Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: A phase II randomized study

Oncology Reports

Volumn 5, Issue 6, 1998, Pages 1499-1505

  Mantovani, Giovanni ^a   Ghiani, Massimo ^a   Lai, Paola ^a   Macciò, Antonio ^a   Dessì, Daniela ^a   Succu, Giovanna ^a   Massa, Daniela ^a   Curreli, Luigi ^a   Mulas, Carlo ^a   Esu, Silvia ^a   Proto, Ernesto ^a   Cadeddu, Gabrio ^b   Tore, Giorgio ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b SS Trinit Hospital   (Italy)

Author keywords

Cisplatin; Itbsfamide; Neo adjuvant chemotherapy; Phase II randomized study; Quality of life; Stage III IV head and neck cancer

Indexed keywords

CISPLATIN; IFOSFAMIDE; INTERLEUKIN 2; INTERLEUKIN 6; MESNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HEMATOLOGIC DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; SINGLE-BLIND METHOD; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031668296     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.6.1499     Document Type: Article

References (29)

1. Al Sarraf M: Head and neck cancer: chemotherapy concepts. Semin Oncol 15:70-85, 1988.
2. Gebbia V, Zerillo G, Gebbia N, et al: Chemotherapy in head and neck cancer (I): management of recurrent or metastatic disease. J Chemother 4: 244-259, 1992.
3. Choksi AJ, Dimery IW and Hong WK: Adjuvant chemotherapy of head and neck cancer; the past, the present, the future. Semin Oncol 15:45-59, 1988.
4. O'Brian PH, Carlson R, Steubber EA, et al: Distant metastases in epidermoid cell carcinoma of the head and neck. Cancer 27: 304-307, 1971.
5. Scanlon KJ, Newman EM, Lu Y, et al: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923-8926, 1986.
6. Schabel FM, Trader MW, Laster WR, et al: Cis-diamminodichloroplatinum: combination chemotherapy and cross resistance studies with tumor of mice. Cancer Treat Rep 83: 1459-1463, 1979.
7. Kish J, Drelichman A, Jacobs J, et al: Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 66: 471-474, 1981.
8. Drings P, Allner R, Brock N, et al: Erfahrungen mit neuartigen N-Lost Phosphamidestem. Dtsch Med Wochenschr 95: 491-497, 1970.
9. Legent F and Beanvillain C: Experimentation clinique de l'Holoxan 1000. Quest Med 6: 377-380, 1978.
10. Freche C: Essai de l'Holoxan 1000 dans les cancers ORL. Gaz Med France 10: 1081-1083, 1978.
11. Serrou B: Evaluation de l'Holoxan 1000 dans les tumeurs ORL avancès. Extension aux cancers anaplasiques des bronches. Rev Mediterranean Sci Med 2: 137-138, 1978.
12. Focan C, Salamon E, Legungs F, et al: Efficacité d'une chimiotherapie sequentielle incluant la vincristine, le cisplatine et l'ifosfamide dans le traitement des carcinomes de la tête et du cou stade IV et des melanomes avec atteinte viscerale. Bull Cancer 71: 105-107, 1984.
13. Pai VR, Parikh DM, Mazumdar AT, et al: Phase II study of high dose ifosfamide as single agent and in combination with cisplatin in the treatment of advanced and/or recurrent squamous cell carcinoma of head and neck. Oncology 50: 86-91, 1993.
14. International Union Against Cancer: TNM Classification of Malignant Tumors. 4th edition, 2nd revision. Hermanek P and Sobin LH (eds.) Springer, Berlin, 1992.
15. Beahrs OH, Henson DE, Mutter RVP and Myers MH (eds.): Manual for Staging of Cancer. 3rd edition. American Joint Committee on Cancer. Lippincott, Philadelphia, 1988.
16. Miller AB, Hoogstraten B, Staquet M and Wrnkler M: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
17. Cella DF, Tulsky DS, Gray G, et al: The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11: 570-579, 1993.
18. Mantovani G, Macciò A, Pisano M, et al: Tumor-associated lymphomonocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int J Cancer 71: 724-731, 1997.
19. Kish J, Drelichman A, Jacobs J, et al: Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 66: 471-476, 1982.
20. Rooney M, Kish J, Jacobs J, et al: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 55: 1123-1128, 1985.
21. Thyss A, Schneider M, Santini J, et al: Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br J Cancer 54: 755-760, 1986.
22. Kies MS, Gordon LI, Hauck WW, et al: Analysis of complete responders after initial treatment with chemotherapy in head and neck cancer. Laryngol Head Neck Surg 93: 199-205, 1985.
23. Lemke S, Chung CT, Kellman R, et al: Phase II trial of ifosfamide mesna. cisplatin and ethacrynic acid in the treatment of advanced squamous cell carcinoma of the head and neck. XVI Int. Cancer Congress, UICC Satellite Symposium. Treatment of Head and Neck Cancer. New Delhi, pp24-29, 1994.
24. Cervellino JC, Francia A, Araujo CE, et al: Treatment of advanced head and neck cancer with ifosfamide/mesna plus carboplatin. XVI Int. Cancer Congress. UICC Satellite Symposium. Treatment of Head and Neck Cancer. New Delhi, pp6-10, 1994.
25. Mantovani G, Macciò A, Bianchi A, et al: Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 25: 135-141, 1995.
26. Yokes EE and Athanasiadis I: Chemotherapy for squamous cell carcinoma of head and neck: The future is now. Ann Oncol 7: 15-29, 1996.
27. Catimel G, Verweij J, Mattijssen V, et al: Docetaxel (taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 533-537, 1994.
28. Murphy BA: New drug therapy for squamous carcinoma of the head and neck. Curr Opin Oncol 8: 221-226, 1996.
29. Shewach DS and Lawrence TS: Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 14: 257-263, 1996.